Genetic Rx Conference 12-3-15

Prominent academics, leaders of the biopharmaceutical industry and key investors will gather on December 3rd at Genetic Rx, a networking conference of the Boston Biotech Conferences series. Genetic Rx will take place at the Joseph B. Martin Conference Center at Harvard Medical School and will discuss the present and future of genetic therapies, pricing, reimbursement, the regulatory landscape as well as the treatment of patients with rare and ultra-rare genetic diseases.

Boston, MA (PRWEB) November 18, 2015

Prominent academics, leaders of the biopharmaceutical industry and key investors will gather on December 3rd at Genetic Rx, a networking conference of the Boston Biotech Conferences series. Genetic Rx will take place at the Joseph B. Martin Conference Center at Harvard Medical School and will discuss the present and future of genetic therapies, pricing, reimbursement, the regulatory landscape as well as the treatment of patients with rare and ultra-rare genetic diseases.
Speakers include Jörn Aldag (uniQure), George Church (Harvard Medical School), JC Gutierrez Ramos (Synlogic Therapeutics), Kathy High (Spark Therapeutics), Edward Kaye (Sarepta), Henrik Ørum (Roche), Mene Pangalos (Astrazeneca), Peter Saltonstall (NORD), Akshay Vaishnaw (Alnylam), James Wilson (University of Pennsylvania) among others. Leading investors from Bain Capital, Wellington Management Company, Pioneer Investments, Deerfield Partners, Fidelity Investments, Sofinnova Ventures, and Third Rock Ventures will also be in attendance.
“After attending Genetic Rx 2014, I’m looking forward to this year’s conference. As discoveries in a broad range of genetic therapies continue to develop, this conference is an excellent opportunity to catch up on progress and network with fellow thought leaders focused on the advancement of novel treatments and potential cures for multiple diseases” says Edward Lanphier, President and CEO of Sangamo BioSciences. “This intimate and off-the-record forum allows for high quality of exchanges and I am happy to be a part of it.”
Mark Pykett, President and CEO of Agilis Biotherapeutics says of the event: "The momentum of the field of genetic medicine is mirrored in the energy of BBC's Genetic Rx Conference. As the field confronts the consequences of increasing success, leaders from genetic medicine gather at the Genetic Rx Conference to exchange ideas and address the challenges and opportunities they face, and to collaborate on capturing the promise of this important, emerging area of medicine."
“During the last 100 years we treated signs and symptoms with small molecules. Antibodies and proteins have been part of the armamentarium to treat disease for the last 40 years. Now we are seeing the explosion of therapeutic opportunities in genetic medicines becoming a reality: gene therapy, gene editing, RNA silencing and synthetic biology. The intense and fast pace approach of the GeneticRX conference allows a deep dive to participants and helps to propel the field forward”, says Belen Carrillo-Rivas, Head of R&D Innovation Projects at Pfizer.
Genetic Rx is sponsored by Alexandria Real Estate Equities, H.C. Wainwright, Alnylam Pharmaceuticals, Agilis Biotherapeutics, Isis Pharmaceuticals, Mintz Levin, Pfizer and the BioPharma Executive Council.
For more information, please visit: http://bbbiotechconference.com/conference-agenda.php?id=35
ABOUT THE BOSTON BIOTECH CONFERENCES (BBC)

8:30-9:10 am

Genetic Therapies: 2015 Milestones and 2016 GoalsKatherine High, Spark Therapeutics; Eirene Kontopoulos, Fidelity; Edward Lanphier, Sangamo BioSciences; Ken Mills, Regenxbio; Joshua Schimmer, Piper Jaffray Moderator: Jon Kravetz, Mintz Levin